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Abstract
Introduction: Estrogen is a driver in the growth and progression of gynecologic cancers (cervical, ovarian, and
uterine). A number of estrogenically active chemicals are suspected to contribute in the development of gynecologic
lesions, including an increased risk of estrogen-dependent cancer in women. Humans are exposed to estrogenic
endocrine disruptors (EEDs), such as- polychlorinated biphenyls (PCBs), phthalates and bisphenol A (BPA).
Therefore, we examined the cross-sectional relationship between exposure to PCBs, phthalates, and BPA and
gynecologic cancers (cervical, ovarian, and uterine).
Methods: We analyzed data from female participants (20 years of age and older) who provided blood and urine
samples for the Centers for Disease Control and Prevention’s National Health and Nutrition Examination Survey
(NHANES) between 1999 and 2010. Exposure was examined based on lipid adjusted serum levels of 6 individual
PCB congeners (74, 99, 118, 138, 153, and 180), the sum of dioxin-like PCBs (074 and 118), the sum of non-dioxin-
like PCBs (099+138+153+187), 8 urinary phthalate metabolites (MNP, MEP, MEHP, MBzP, MCPP, MEHHP, MEOHP,
and MIB), the sum of DEHP metabolites (MHP+MHH+MOH), the sum of total phthalates, and urinary BPA in
conjunction with data obtained from the medical and reproductive health questionnaires. We calculated geometric
means to compare EEDs concentrations in women who self-reported a cervical, ovarian, or uterine cancer diagnosis
vs. women who self-reported never being diagnosed with cancer. We used logistic regression models to estimate
odds ratios (ORs) and 95% confidence intervals (CIs) for the association between exposure to EEDs and r
gynecologic cancers. We also evaluated age, race/ethnicity, body mass index (BMI; kg/m2), and age at menarche as
potential confounding variables in our final models.
Results: Separate analyses showed weighted geometric mean (GM) levels of individual PCB congeners to be
significantly higher among women with ovarian cancer, and uterine cancer when compared to the rest of the study
population. Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) was found to be significantly higher and BPA was
higher among women with ovarian cancer compared to women never diagnosed with any gynecologic cancer. After
adjusting for age, race, BMI, and age at menarche, we found that PCB 138 was significantly associated with cervical
cancer, and uterine cancer [odds ratios of 3.05, 95% CI: 1.21-7.69; and 5.83, 95% CI: 1.63-20.9], respectively. PCB
74 and 118 however, were significantly associated with ovarian cancer with an odds ratios of 6.47, 95% CI:
1.23-3.41 (for PCB 74) and 6.68, 95% CI: 1.39-32.3 (for PCB 118). We also found the sum of non-dioxin-like PCBs
to be significantly associated with uterine cancer (OR of 1.12, 95% CI: 1.03-1.23) and the sum of dioxin-like PCBs to
be significantly associated with ovarian cancer (OR of 2.02, 95% CI: 1.06-3.85). We did not find significant
associations between urinary phthalates and BPA and gynecologic cancers.
Conclusions: Our findings point to a possible association between environmental exposure to PCBs and an
increased risk of cervix, ovarian and uterine cancer. However, these findings should be interpreted cautiously
because of self-reported cross sectional data and a limited sample size of gynecologic cancers.
Keywords: NHANES; PCBs; Phthalates; BPA; EDC; Gynecologic
cancers
Introduction
Based on 2009-2013 survey, NCI SEER 2016 estimates that the
number of new cases of gynecologic cancers- cervical, endometrial and
ovarian was 7.5, 25.4 and 11.9 per 100,000 women per year,
respectively [1]. However, in terms of deaths, ovarian cancer leads to
more deaths than uterine and cervical cancers. To prevent new
incidence of gynecologic cancers, it is important to understand the
associated environmental and molecular risk factors. In most cases, the
exact cause of these cancers is not known. Genetics can only account
for 5-10% of gynecologic cancer risks and the rest possibly can be
attributed to hormonal and environmental influences.
Epidemiologic studies support unopposed elevated levels of
estrogen exposure including endocrine-active chemicals and their
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association with increased risk of developing cervical, ovarian and
endometrial cancers [2-8]. A recent report by the United Nations
Environment Program (UNEP) and WHO highlighted the increasing
rates of endocrine-related cancers over the past 40-50 years in
conjunction with approximately 800 chemicals that are suspected to
act as endocrine disruptors [9,10]. Many of these chemicals are used in
a variety of consumer products; therefore, exposure to endocrine
disrupting chemicals among general population is widespread. Human
exposure to endocrine disrupting chemicals may result from inhalation
from air, absorption through the skin, and most commonly through
the ingestion of contaminated food and water [11]. Human
populations are constantly exposed to a wide variety of estrogenic
endocrine disruptors (EEDs). Exposure to multiple EEDs, such as
polychlorinated biphenyls (PCBs), phthalates, and bisphenol A (BPA)
have been detected in 90% of blood and urine samples collected
[12-14] in various human studies during the last decade.
The role of EEDs, in the etiology of some of the human gynecologic
cancers and reproductive health hazards, has been implicated,
although the linkage between these two processes is highly
controversial [2-8]. In rodent experimental models, neonatal exposure
to DES, dioxin-like compounds, 2,2',4,4',5,5'-hexachlorobiphenyl
(PCB153); 2,3',4,4',5-pentachlorobiphenyl (PCB118); hydroxylated
polychlorinated biphenyls BPA affects the adult uterine response to
hormone and induces reproductive lesions including uterotrophy,
uterine hyperplasia and cancer, cervicovaginal (CV) tract carcinomas
[15,16]. Animal studies have linked PCB exposure to decreased sperm
fertilizing ability in mice [17], changes in the uterine myometrium
[18], and exhibited a significant dose-dependent relationship in the
prevalence and severity of endometriosis in rhesus monkeys [19].
Among various phthalates, di (2-ethylhexyl) phthalate (DEHP), di-
butyl phthalate (DBP) and butylbenzyl phthalate (BBP) have been
studied for their endocrine disrupting effects. Phthalates were shown
to produce anti-androgenic effects by suppressing testosterone and
oestrogen production. At very high phthalate levels, reproductive
abnormalities were reported in rodent females which included
increased uterine and ovarian weights, and delayed onset of puberty
[20]. In our earlier study [21], we have shown that bisphenol A (BPA)
is oxidized to bisphenol-o-Quinone by cytochrome P450 activation
system. Administration of a single dose or multiple doses of 200 mg/kg
of BPA to CD1 male rats produced in vivo DNA adducts with
matching dGMP-bis-phenol-o-Quinone profile. Further, covalent
modifications in DNA by in vivo exposure of BPA are suspected to be a
factor in the induction of endocrine toxicity [21]. In rodent females,
BPA exposure has shown to cause alterations in the mammary gland
development, changes in gene expression of the mammary gland and
many other gynecological cancer related disorders and impairments.
For example, BPA exposure has also been shown to cause cystic
ovaries, endometrial hyperplasia, adenomyosis, leiomyomas, atypical
hyperplasia, stromal polyps, ductal hyperplasias and carcinoma, a
decline in fertility and fecundity, decreased wet weight of the vagina,
decreased volume of the endometrial lamina propria, and an increased
expression of estrogen receptor-α (ERα) and progesterone receptors
[20,22-27]. Estrogen is a major driver in the growth and progression of
gynecologic cancers (cervix, ovary, and uterus) [2-4,28-30]. PCBs,
BPA, and phthalates are extensively studied estrogenically active
chemicals, and therefore, our objective of this study was to use the
available National Health and Nutrition Examination Survey
(NHANES) data (1999-2010) to assess the association of gynecologic
cancers (cervix, ovarian, and uterine) with exposure to these three
selected classes of EEDs: PCBs, BPA, and phthalates.
Methods
Study design and population
We obtained blood serum concentrations of individual PCB
congeners (6 individual PCB congeners, the sum of dioxin-like PCBs,
and the sum of non-dioxin-like PCBs) and urinary phthalates and
bisphenols data from the NHANES (http://www.cdc.gov/nchs/nhanes/
index.htm) as described by Marissa et al. [8].
Gynecologic cancers data collection
We included female NHANES participants of 25 to 85 years of age
who completed the physical exam, reproductive questionnaire, and
medical health questionnaire and provided a response for “Have you
ever been told by a doctor or other health professional that you had
cancer or a malignancy of any kind?” Women who answered “yes”
were subsequently asked “What kind of cancer was it?”
A total of 8,315 women who provided a response in the 1999-2004
survey cycles to for “Have you ever been told by a doctor or other
health professional that you had cancer or a malignancy of any kind?”
question. After removing the observations that did not include PCB
data, our PCB study population consisted of 2,072 participants: 27
reported a cervical cancer diagnosis, 11 reported an ovarian cancer
diagnosis and 26 reported a uterine cancer diagnosis and women who
did not report a cancer diagnosis ranged from 1955 to 1962 depending
on the PCB congener being evaluated.
Our phthalate study population consisted of women of 20 to 85
years of age who provided a response in the 2003-2010 survey years to
“Have you ever been told by a doctor or other health professional that
you had cancer or a malignancy of any kind?” question. After
removing creatinine observations that were <30 mg/dL and >300
mg/dL our study populations consisted of 3,003 participants of whom
28 reported a cervical cancer diagnosis, 20 reported an ovarian cancer
diagnosis, 27 reported a uterine cancer diagnosis and 2,731 reported
no cancer diagnosis.
Our BPA study population consisted of women of 20 to 85 years of
age provided a response in the 2005-2010 survey cycles to for “Have
you ever been told by a doctor or other health professional that you
had cancer or a malignancy of any kind?” question. After removing
creatinine observations that were <30 mg/dL and >300 mg/dL our
study populations consisted of 2,202 participants of whom 16 reported
a cervical cancer diagnosis, 16 reported an ovarian cancer diagnosis,
22 reported a uterine cancer diagnosis, and 2,070 reported no cancer
diagnosis.
Statistical analysis
Due to a small number of cervical, ovarian, and uterine cancer
cases, we conducted logistic regression analyses using the following
two groups: Level of detection (LOD) to 50th percentile (reference) vs.
≥ 50th percentile. We also conducted separate analyses on females with
serum PCB, phthalate, and BPA levels >LOD where gynecologic
cancers cases were compared with non-cancer cases. Significance was
set at p <0.05. As described in our recent paper [8], using PROC
SURVEYLOGISTIC, we derived unadjusted and adjusted odds ratios
(ORs) and their 95% confidence intervals (CIs) to evaluate the
association between exposure to EEDs and cervical cancer, ovarian
cancer, or uterine cancer. We conducted separate analyses for the sum
of dioxin-like and non-dioxin-like PCBs and individual PCB
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congeners and gynecologic cancers. Due to a small number of cervical,
ovarian, and uterine cancer cases, ORs and 95% CIs were calculated
using the following group: <LOD to 50th percentile vs. ≥ 50th
percentile. The reference group for each PCB congener is defined as
those participants whose serum concentrations were <LOD to 50th
percentile.
Covariates
The following potential confounders were either self-reported in the
questionnaire interviews or taken as a laboratory measurement. The
demographic variables of age at interview (20-59 years, 60-74 years,
and ≥ 75 years), race (white vs. other) were obtained during the
NHANES home interview [8]. Reproductive variables including age at
menarche (<12 years, 12-14 years, ≥ 15 years), parity (0, 1, ≥ 2), oral
contraceptive use (yes/no) and lactation (yes/no) as well as lifestyle
variables including smoking (yes/no) and alcohol use (yes/no) were
obtained from health questionnaires completed in the mobile
examination center. Body mass index (<25 kg/m2, 25 to <30 kg/m2 and
≥ 30 kg/m2) was obtained through the body measurement component
in the mobile examination center [23]. For all EEDs, ORs and 95% CIs
are reported for three models: unadjusted; age and race/ethnicity
adjusted; and age, race/ethnicity, BMI, and age at menarche adjusted.
Parity and oral contraceptive use, and lactation were not included in
the models because of the extent of missing data. Smoking history and
alcohol consumption were not significant predictors of gynecologic
cancer risk and therefore were also not presented in the final models.
Results
PCB Descriptive Statistics
The study population included 2,008 female participants of 20 years
of older age with available PCB data and who completed the medical
conditions questionnaire and provided a response to “Have you ever
been told by a doctor or other health professional that you had cancer
or a malignancy of any kind?” question. Women who answered “yes”
were subsequently asked, “What kind of cancer was it?” question.
Among the women who reported no cancer or a gynecological cancer:
1,965 (91.5%) reported never being diagnosed with cancer, 43 (2.14%)
reported being diagnosed with cervical cancer, 11 (0.56%) reported
being diagnosed with ovarian cancer, and 26 (1.31%) reported being
diagnosed with uterine cancer (Table 1). Study participants were fairly
evenly distributed between the two races: 48.6% were of non-Hispanic
white ethnicity group and 51.4% were classified the group ‘Other’. The
majority of participants were 20-59 years of age at the time of
interview (65.9%) (Table 1). The mean age at the time of interview was
45.6 years for the women who reported to have never been diagnosed
with cancer, 47.5 years, 52.0 years, and 52.4 years for women who
reported being diagnosed with cervical cancer, ovarian cancer, and
uterine cancer, respectively. The mean age at diagnosis was 30.6 years,
41.9 years, and 53.2 years for women diagnosed with cervical cancer,
ovarian cancer, and uterine cancer, respectively (Table 1). BMI was
normal (<25 kg/m2) for 35.5%, overweight (25 to <30 kg/m2) for
28.6%, and obese (≥ 30 kg/m2) for 39.0% of study participants. The
majority of study participants reported an age of menarche of 12-14
years (64%), ≥ 2 live births (71.4%), responded yes to breastfeeding
(57.6%), responded yes to oral contraceptive use (58.8%), responded
no to a history of smoking (57.8%), and yes to alcohol consumption
(54.5%) (Table 1).
Cervical
Cancer
Ovarian
Cancer
Uterine
Cancer
Variables n (%) n(%) n(%)
Total Population (n, %) 27 (1.36%) 11 (0.56%) 26 (1.31%)
Age at interview (years; mean
± se) 47.5 ± 2.61 52.0 ± 3.75 52.4 ± 5.17
Age at diagnosis (years; mean
± se) 30.6 ± 1.14 41.9 ± 1.97 53.2 ± 1.52
Race/Ethnicity1
Non-Hispanic white 19 (0.95%) 6 (0.30%) 17 (0.85%)
Other 8 (0.40%) 5 (0.25%) 9 (0.45%)
Age (years)
20-59 18(0.90%) 7 (0.35%) 11 (0.55%)
60-74 6 (0.30%) 3 (0.15%) 11 (0.55%)
≥ 75 3 (0.15%) 1 (0.05%) 4 (0.20%)
Age at menarche (years)
<12 years 10 (0.56%) 2 (0.11%) 7 (0.39)
12-14 years 14 (0.79%) 6 (0.34%) 14 (0.78%)
≥ 15 years 0 (0.00%) 2 (0.11%) 4 (0.22%)
Parity (no. of live births)
0 3 (0.19%) 1 (0.07%) 1 (0.06%)
1 4 (0.26%) 2 (0.13%) 5 (0.32%)
>2 16(1.04%) 6 (0.39%) 18 (1.16%)
BMI (kg/m2)
Normal weight (18.5 to <25) 16 (0.80%) 4 (0.20%) 12 (0.60%)
Overweight (25 to <30) 16 (0.80%) 4 (0.20%) 8 (0.40%)
Obese (≥ 30) 9 (0.45%) 3 (0.15%) 8 (0.40%)
Breastfed
Yes 12 (0.85%) 5 (0.36%) 13 (0.92%)
No 8 (0.57%) 3 (0.21%) 10 (0.71%)
Oral Contraceptive Use
Yes 18 (0.98%) 6 (0.33%) 12 (0.66%)
No 6 (0.33%) 4 (0.22%) 14 (0.76%)
Ever Smoked
Yes 13 (0.65%) 7 (0.35%) 16 (0.80%)
No 14 (0.70%) 4 (0.20%) 10 (0.50%)
Alcohol Use
Yes 10 (0.55%) 7 (0.38%) 17 (0.93%)
No 15 (0.85%) 3 (0.16%) 9 (0.49%)
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Estimated percent distribution after applying NHANES sampling weights.
Table 1: Descriptive statistics for gynecological cancer status and
selected covariates among women ≥ 20 years of age with serum PCB
measurements, NHANES 1999-2004. No cancer cases in total
Population (n,%) 1965 (91.5%) Age at interview (years; mean ± se)
45.6 ± .42.
Phthalate and BPA descriptive statistics
The study population included 3,003 female participants of 20 years
of age and older age with available phthalate and/or BPA data and who
completed the medical conditions questionnaire and provided a
response for “Have you ever been told by a doctor or other health
professional that you had cancer or a malignancy of any kind?”
question.Women who answered “yes” were subsequently asked, “What
kind of cancer was it?” and “What was your age at diagnosis?”
question. Among the 3,003 participants, 2,731 (90.4%) reported never
being diagnosed with cancer, 28 (0.65%) reported being diagnosed
with cervical cancer, 20 (0.47%) reported being diagnosed with ovarian
cancer, and 27 (0.63%) reported being diagnosed with uterine cancer
(Table 2). The mean age at diagnosis was 30.5 years, 46.3 years, and
52.3 years for women diagnosed with cervical cancer, ovarian cancer,
and uterine cancer, respectively (Table 2). BMI was normal (<25
kg/m2) for 28.3%, overweight (25 to <30 kg/m2) for 28.6%, and obese
(≥ 30 kg/m2) for 39.3% of study participants. The majority of study
participants reported age of menarche at 12-14 years (62.1%), ≥ 2 live
births (74.0%), responded yes to breastfeeding (54.9%), and responded
yes to oral contraceptive use (63.4%), responded no to a history of
smoking (58.4%), and yes to alcohol consumption (57.1%) (Table 2).
Variables Cervical
Cancer n(%)
Ovarian
Cancer n(%)
Uterine
Cancer n(%)
Total Population (n,%) 28 (0.65%) 20 (0.47%) 27 (0.63%)
Age at interview (years; mean ±
se)
48.1 ± 2.71 56.1 ± 5.09 58.3 ± 3.10
Age at diagnosis (years; mean
± se)
30.5 ± 0.76 46.3 ± 1.42 52.3 ± 2.04
Race/Ethnicity1
Non-Hispanic white 18 (0.65%) 9 (0.33%) 20 (0.73%)
Other 10 (0.36%) 11 (0.40%) 7 (0.25%)
Age (years)
20-59 24 (0.87%) 11 (0.40%) 8 (0.29%)
60-74 3 (0.11%) 6 (0.22%) 11 (0.40%)
≥ 75 1 (0.04%) 5 (0.18%) 8 (0.29%)
Age at menarche (years)
<12 years 1 (0.04%) 4 (0.16%) 5(0.20%)
12-14 years 18 (0.73%) 10 (0.41%) 17 (0.69%)
≥ 15 years 3 (0.12%) 3 (0.12%) 5 (0.20%)
Parity (no. of live births)
0 1 (0.05%) 0 (0.00%) 0 (0.00%)
1 4 (0.20%) 4 (0.20%) 1 (0.21%)
>2 4 (0.20%) 11 (0.55%) 4 (0.82%)
BMI (kg/m2)
Normal weight (18.5 to <25) 7 (0.26%) 3 (0.11%) 6 (0.22%)
Overweight (25 to <30) 7 (0.26%) 12 (0.44%) 6 (0.22%)
Obese (≥30) 14 (0.51%) 5 (0.18%) 15 (0.55%)
Breastfed
Yes 15 (0.77%) 7 (0.36%) 11 (0.56%)
No 10 (0.51%) 8 (0.41%) 15 (0.77%)
Oral Contraceptive Use
Yes 21(0.84%) 7 (0.28%) 15 (0.60%)
No 5 (0.20%) 10 (0.40%) 12 (0.48%)
Ever Smoked
Yes 21 (0.76%) 6 (0.22%) 13 (0.47%)
No 7 (0.25%) 14 (0.51%) 14 (0.51%)
Alcohol Use
Yes 19 (0.76%) 6 (0.24%) 14 (0.56%)
No 7 (0.28%) 11 (0.44%) 13 (0.52%)
Table 2: Descriptive statistics for gynecological cancer status and
selected covariates among women ≥ 20 years of age with urinary
phthalate and bisphenol a measurements, NHANES 2003-2010.
Estimated percent distribution after applying NHANES sampling
weights. Total Population with no cancer (n, %) 2731 (90.4%) Age at
interview (years; mean ± se) 45.3 ± .40
Geometric mean1(ng/g) (GSE,n)
PCB Metabolites2 Cervical Cancer Ovarian
Cancer
Uterine
Cancer
PCB 074 9.58 (1.21, 27) 30.0 (1.32,
11)b
10.8 (1.21,
26)
PCB 099 6.82 (1.16, 26) 51.9 (1.32,
11)b
7.24 (1.21,
25)
PCB 118 12.2 (1.25, 27) 38.9 (1.38,
11)b
11.1 (1.32,
26)
PCB 138 12.2 (1.25, 27) 22.3 (1.36,
11)b
30.9 (1.14,
26)b
PCB 153 12.2 (1.25, 27) 12.2 (1.42,
11)b
40.9 (1.15,
26)b
PCB 180 23.8 (1.17, 27) 16.6 (1.28, 11) 30.3 (1.20,
26)b
Phthalate Metabolites3
MBP 1.92 (1.04, 28) 1.93 (1.04, 20) 2.03 (1.07,
27)
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MEP 2.86 (1.04, 28) 1.93 (1.04, 20) 3.10 (1.16,
27)b
MEHP 1.20 (1.05, 28) 1.36 (1.05, 20) 1.07 (1.07,
27)
MBzP 1.51 (1.05, 28) 1.68 (1.07, 20) 1.46 (1.08,
27)
MCCP 1.18 (1.05, 28) 1.26 (1.09, 20) 1.20 (1.04,
27)
MEHHP 1.88 (1.05, 28) 2.32 (1.25,
20)b
1.93 (1.08,
27)
MEOHP 1.77 (1.05, 28) 2.03 (1.28, 20) 1.72 (1.08,
27)
MIB 1.39 (1.04, 28) 1.46 (1.06, 20) 1.46 (1.09,
27)
DEHP4 3.34 (1.17, 28) 6.55 (2.08, 20) 3.53 (1.23,
27)
Total Phthalates5 54.6 (1.31, 28) 102 (1.54, 20) 56.8 (1.22,
27)
Bisphenol A6
BPA 1.17 (1.08, 16) 1.23 (1.08, 16) 1.09 (1.06,
22)
Table 3: Geometric Mean of serum PCB or urinary phthalate levels
(ng/g) by gynecological cancer status for women ≥ 20 years of age.
1Geometric means calculated after applying NHANES sampling
weights. 2Lipid adjusted and log transformed polychlorinated
biphenyls (ng/g); NHANES 1999-2004. PCB metabolites in no cancer
cases (GM, SE and n): PCB 074-8.08 (1.03, 1960), PCB099-5.99 (1.03,
1958), PCB118- 9.49 (1.03, 1960), PCB-138, 20.9 (1.03, 1961)
PCB153-28.8 (1.02, 1962), PCB 180-19.5 (1.02, 1955). 3Log
transformed and creatinine corrected urinary phthalate metabolites
(ng/mg); NHANES 2003-2010. Phthalate Metabolites in no cancer
cases (GM, SE and n). MBP-1.93 (1.01, 2723), MEP- 2.83 (1.01, 2723),
MEHP- 1.19 (1.01, 2723), MBzP- 1.54 (1.01, 2723)d, MCCP-1.21 (1.01,
2723), MEHHP-1.90 (1.01, 2723), MEOHP-1.72 (1.01, 2723),
MIB-1.46 (1.01, 2723), DEHP4-3.86 (1.03, 2723), Total Phthalates
5-58.0 (1.04, 2723), 4DEHP=Sum of MEHP, MEHHP and MEOHP.
5Total Phthalates=Sum of MBP, MEP, MEHP, MBzP, MCCP, MEHHP,
MEOHP and MIB. 6Log transformed and creatinine corrected urinary
BPA measurements (ng/g); NHANES 2005-1010. BPA in no cancer
cases (GM, SE and n). 1.16 (1.01, 2070) c PCB or phthalate levels
significantly higher in women with cancer vs. women without cancer;
ap<0.0001, bp<0.05. BPA significantly higher in women without cancer
vs. women with breast cancer, cp<0.05. MBzP is significantly higher in
women without cancer vs. women diagnosed with breast cancer,
dp<0.05.
Table 3 presents GMs+GSEs of EEDs by gynaecologic cancer status.
PCB 74, 99, 118, 138, and 153 were significantly higher in women
diagnosed with uterine cancer and PCB 138, 153, and 180 were
significantly higher in women diagnosed with uterine cancer
compared to women never diagnosed with cancer. None of the PCB
congeners were significantly higher in women diagnosed with cervical
cancer (Table 3 and Figure 1). MHH was significantly higher in women
diagnosed with ovarian cancer compared to women never diagnosed
with cancer (Table 3 and Figure 2). MHP was the only phthalate found
to be significantly higher among women with a gynaecologic cancer
compared to women never diagnosed with cancer. Women diagnosed
with a gynaecologic cancer did not have significantly higher levels of
BPA compared to women never diagnosed with cancer (Table 3).
Figure 1: Geometric Mean PCB levels (ng/g) by cancer status for
women ≥ 20 years of age, NHANES 1999-2004.
Figure 2: Geometric mean urinary phthalate levels (ng/mg) in
women ≥ 20 years of age, NHANES 2003-2010.
GM of EED levels were also examined by cancer status in women
with individual PCB concentrations with >LOD (Table 4). PCB 74, 99,
118, 138, and 153 were significantly higher in women diagnosed with
ovarian cancer, and PCB 138 was significantly higher in women
diagnosed with uterine cancer compared to women never diagnosed
with cancer. For women with phthalate concentrations >LOD, GM
levels did not differ between women diagnosed with a gynecologic
cancer and women never diagnosed with cancer (Table 4). When
observations <LOD were removed, BPA became significantly higher in
women diagnosed with cervical cancer compared to women never
diagnosed with cancer (Table 4).
Geometric mean1 (ng/g) (GSE,n)
Cervical Cancer Ovarian
Cancer
Uterine
Cancer
PCB Metabolites2
PCB 074 10.7 (1.25, 24) 21.8 (1.19,
9)a
10.9 (1.21, 23)
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PCB 099 7.61 (1.21, 21) 20.1 (1.21,
8)b
8.50 (1.22, 19)
PCB 118 14.4 (1.29, 24) 30.9 (1.25,
9)a
12.9 (1.25, 23)
PCB 138 28.2 (1.22, 24) 47.5 (1.38,
9)b
31.5 (1.14,
25)b
PCB 153 37.7 (1.21, 25) 63.4
(1.35,9)b
41.3 (1.15, 25)
PCB 180 25.0 (1.17, 25) 37.7 (1.36,
9)
30.9 (1.21, 24)
Phthalate Metabolites3
MBP 1.92 (1.04, 28) 1.93 (1.04,
20)
2.03 (1.08, 27)
MEP 2.86 (1.04, 28) 2.64 (1.05,
20)
3.10 (1.16,
27)b
MEHP 1.45 (1.06, 18) 1.55 (1.27,
16)
1.16 (1.04, 19)
MBzP 1.51 (1.05, 28) 1.68 (1.07,
20)
1.46 (1.05, 27)
MCCP 1.19 (1.05, 28) 1.26 (1.09,
20)
1.20 (1.05, 27)
MEHHP 1.88 (1.06, 28) 2.32 (1.25,
20)
1.93 (1.04, 27)
MEOHP 1.77 (1.05, 28) 2.03 (1.28,
20)
1.72 (1.08, 27)
MIB 1.43 (1.04, 28) 1.46 (1.06,
20)
1.46 (1.06, 27)
Bisphenol A6
BPA 1.27 (1.05, 14)a 1.30 (1.08,
15)
1.09 (1.06, 22)
Table 4: Geometric Mean PCB or urinary phthalate levels (ng/g) by
gynecological cancer status for women ≥ 20 years of age with
concentrations above the LOD. 1Geometric means calculated after
applying NHANES sampling weights. 2Lipid adjusted and log
transformed polychlorinated biphenyls (ng/g); NHANES 1999-2004.
PCB metabolite levels in no cancer cases (GM, SE n). PCB 074-9.87
(1.03, 1484), PCB 099-7.24 (1.02, 1334), PCB 118-11.7 (1.03, 1534),
PCB 138 -23.6 (1.03, 1594), PCB 153-31.8 (1.03, 1651), PCB 180- 23.3
(1.03, 1600). 3Log transformed and creatinine corrected phthalate
metabolites (ng/mg); NHANES 2003-2010. Phthalate metabolite in no
cancer cases (GM, SE n). MBP-1.93 (1.01, 2718), MEP- 2.83 (1.01,
2722), MEHP- 1.34 (1.01, 1913), MBzP- 1.55 (1.01, 2704), MCCP- 1.22
(1.01, 2677), MEHHP- 1.90 (1.01, 2719), MEOHP- 1.72 (1.01, 2714),
MIB-1.48 (1.01, 2695). 4Log transformed and creatinine corrected
urinary BPA measurements (ng/g); NHANES 2005-1010. BPA (GM,
SE n). 1.18 (1.01, 1959) PCB, BPA, or phthalate levels significantly
higher in women with cancer vs. women without cancer; ap<0.0001,
bp<0.05
Estimated ORs and 95% confidence intervals (CI) for the risk of
having cervical, ovarian, or uterine cancers cancer and the six
individual PCB congeners are shown in Tables 5-8. Estimated ORs and
95% CIs for the risk of having cervical cancer and the six individual
PCB congeners are shown in Table 6. In unadjusted models, PCBs were
significantly associated with cervical cancer risk for subjects in the
second group (≥ 50th percentile) when compared to the reference
group (<LOD to 50th percentile) for PCB congeners 138 and 153
(Table 5). After adjusting for age and race/ethnicity, PCB138 was the
only congener found to be significantly associated with cervical cancer
(OR of 3.12; 95% CI: 1.32-8.74) (Table 6). In addition, PCB138
remained significantly associated with cervical cancer (OR of 3.05,
95% CI: 1.21-7.69) when adjusted for age, race/ethnicity, BMI,
lactation, and age at menarche (Table 6).
Analyte1 No Cases No. Non cases Unadjusted OR (95% CI) Adjusted OR2 (95% CI) Adjusted OR3 (95% CI)
PCB 074
<LOD to 50% 4 1047 1.00 1.00 1.00
≥ 50% 39 1047 5.82 (2.56-13.1)a 1.62 (0.48-5.38) 1.95 (0.31-12.4)
PCB 099
<LOD to 50% 12 1172 1.00 1.00 1.00
≥ 50% 31 787 3.09 (1.60-5.98)b 1.40 (0.66-2.94) 1.52 (0.62-3.74)
PCB 118
<LOD to 50% 6 999 1.00 1.00 1.00
≥ 50% 37 999 4.34 (1.95-9.70)b 1.38 (0.40-4.78) 1.54 (0.29-8.35)
PCB 138
<LOD to 50% 4 1068 1.00 1.00 1.00
≥ 50% 39 891 7.35 (3.10-17.5)a 3.14 (1.14-8.62)b 2.52 (1.06-5.99)b
PCB 153
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<LOD to 50% 4 1078 1.00 1.00 1.00
≥ 50% 39 882 9.20 (2.30-36.8)b 3.94 (0.58-26.6) 3.15 (0.53-18.6)
PCB 18
<LOD to 50% 4 1148 1.00 1.00 1.00
≥ 50% 39 806 10.6 (3.03-37.1)b 4.33 (0.79-23.6) 3.45 (0.76-15.6)
Table 5: Estimated ORs (95% CIs) of gynecological cancer by concentration of lipid adjusted PCBs, among women ≥ 20 years of age, NHANES
1999-200.4. 1Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 2Adjusted for age and race/ethnicity. 3Adjusted for age, race/
ethnicity, BMI, age at menarche; Cases/Noncases: 40/1754 in 074; 40/1753 inO99; 40/1755 in 118; 40/1756 in 138 and 153; 40/1749 in 180.
Significance ap<0.0001, bp<0.05.
Analyte1 No Cases Noncases Unadjusted OR (95% CI) Adjusted OR2 (95% CI) Adjusted OR3 (95% CI)
PCB 074
<LOD to 50% 12 1048 1.00 1.00 1.00
≥ 50% 15 912 1.26 (0.55-2.87) 1.01 (0.37-2.77) 0.87 (0.28-2.70)
PCB 099
<LOD to 50% 13 11721 1.00 1.00 1.00
≥ 50% 13 787 1.52 (0.81-2.83) 1.53 (0.81-2.88) 1.40 (0.72-2.74)
PCB 118
<LOD to 50% 11 1000 1.00 1.00 1.00
≥ 50% 16 960 1.47 (0.57-3.77) 1.47 (0.57-3.77) 1.28 (0.40-4.04)
PCB 138
<LOD to 50% 9 1070 1.00 1.00 1.00
≥ 50% 18 891 2.96 (1.45-6.06)b 3.12 (1.32-87.40)b 3.05 (1.21-7.69)b
PCB 153
<LOD to 50% 11 1080 1.00 1.00 1.00
≥ 50% 16 882 2.17 (1.04-4.53)b 2.18 (0.86-5.53) 2.46 (0.90-6.67)
PCB 18
<LOD to 50% 14 1149 1.00 1.00 1.00
≥ 50% 13 806 1.75 (0.95-3.23) 1.61 (074-3.50) 1.58 (0.70-3.56)
Table 6: Estimated ORs (95% CIs) of cervical cancer by concentration of lipid adjusted PCBs, among women ≥ 20 years of age, NHANES
1999-2004. 1Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 2Adjusted for age and race/ethnicity. 3Adjusted for age, race/
ethnicity, BMI, age at menarche; Cases/Noncases: 24/1754 in 074; 23/1753 in 099; 24/1755 in 118; 24/1756 in 138 and 153; 24/1749 in 180.
Significance ap<0.0001, bp<0.05.
Estimated ORs and 95% confidence intervals for the risk of having
ovarian cancer and the six individual PCB congeners are shown in
Table 7. In unadjusted models, PCBs were significantly associated with
ovarian cancer risk for subjects in the second group (≥ 50th percentile)
when compared to the reference group (<LOD to 50th percentile) for
PCB congeners 74 and 118 (Table 7). After adjusting for age, race/
ethnicity, BMI, lactation, and age at menarche, PCB 74 and 118
remained significantly associated with ovarian cancer [ORs of 6.47
(95% CI:1.23-34.1) and 6.68 (95% CI:1.39-32.3) respectively] (Table 7).
Analyte1 No Cases Noncases Unadjusted OR (95% CI) Adjusted OR2 (95% CI) Adjusted OR3 (95% CI)
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PCB 074
<LOD to 50% 2 1048 1.00 1.00 1.00
≥ 50% 9 912 5.88 (1.67-207)b 7.31 (1.62-32.9)b 6.47 (1.23-34.1)b
PCB 099
<LOD to 50% 3 11721 1.00 1.00 1.00
≥ 50% 8 787 3.67 (0.65-20.9) 4.15 (0.55-31.3) 3.69 (0.43-31.7)
PCB 118
<LOD to 50% 2 1000 1.00 1.00 1.00
≥ 50% 9 960 5.81 (1.66-20.4)b 7.17 (1.64-31.3)b 6.68 (1.39-32.3)b
PCB 138
<LOD to 50% 4 1070 1.00 1.00 1.00
≥ 50% 7 891 1.22 (0.24-6.28) 1.23 (0.15-9.81) 0.97 (0.12-7.63)
PCB 153
<LOD to 50% 3 1080 1.00 1.00 1.00
≥ 50% 8 882 2.12 (0.49-9.13) 2.36 (0.46-12.0) 2.05 (0.50-8.41)
PCB 18
<LOD to 50% 3 1149 1.00 1.00 1.00
≥ 50% 8 806 2.49 (0.58-10.7) 2.88 (0.53-15.6) 2.55 (0.66-9.85)
Table 7: Estimated ORs (95% CIs) of ovarian cancer by concentration of lipid adjusted PCBs, among women ≥ 20 years of age, NHANES
1999-2004. 1Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 2Adjusted for age and race/ethnicity. 3Adjusted for age, race/
ethnicity, BMI, age at menarche; Cases/Noncases: 10/1754in 074; 10/1753 in 099; 10/1755 in 118; 10/1756 in 138 and 153; 10/1749 in 180.
Significance ap<0.0001, bp<0.05.
Estimated ORs and 95% confidence intervals for the risk of having
uterine cancer and the six individual PCB congeners are shown in
Table 8. In unadjusted models, PCBs were significantly associated with
uterine cancer risk for subjects in the second group (≥ 50th percentile)
when compared to the reference group (<LOD to 50th percentile) for
PCB congeners 138 and 153 (Table 8). After adjusting for age, race/
ethnicity, BMI, lactation, and age at menarche, PCB 138 remained
significantly associated with ovarian cancer [OR of 5.83 (95% CI:
1.63-20.9)] (Table 7).
Analyte1 No Cases Noncases Unadjusted OR (95% CI) Adjusted OR2 (95% CI) Adjusted OR3 (95% CI)
PCB 074
<LOD to 50% 8 1048 1.00 1.00 1.00
≥ 50% 18 912 2.13 (0.63-7.15) 1.41 (0.36-5.55) 1.55 (0.34-7.06)
PCB 099
<LOD to 50% 13 11721 1.00 1.00 1.00
≥ 50% 12 787 1.55 (0.46-5.27) 1.19 (0.28-4.97) 1.43 (0.34-6.06)
PCB 118
<LOD to 50% 10 1000 1.00 1.00 1.00
≥ 50% 16 960 1.60 (0.55-4.63) 1.07 (0.24-4.76) 1.52 (0.39-5.92)
PCB 138
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<LOD to 50% 7 1070 1.00 1.00 1.00
≥ 50% 19 891 4.84 (1.68-13.9)b 4.29 (1.21-15.2)b 5.83 (1.63-20.9)b
PCB 153
<LOD to 50% 8 1080 1.00 1.00 1.00
≥ 50% 18 882 3.71 (1.39-9.89)b 3.14 (0.89-11.0) 4.07 (1.19-14.0)
PCB 18
<LOD to 50% 8 1149 1.00 1.00 1.00
≥ 50% 18 806 2.64 (0.79-8.87) 2.00 (0.60-6.61) 1.70 (0.53-5.45)
Table 8: Estimated ORs (95% CIs) of uterine cancer by concentration of lipid adjusted PCBs, among women ≥ 20 years of age, NHANES
1999-2004. 1Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 2Adjusted for age and race/ethnicity. 3Adjusted for age, race/
ethnicity, BMI, age at menarche; Cases/Noncases: 24/1754 in 074; 24/1753in 099; 25/1755 in 118; 25/1756 in 138 and 153; 25/1749 in 180.
Significance ap<0.0001, bp<0.05.
Estimated ORs and 95% confidence intervals for the risk of having
gynecologic cancers and dioxin-like and non-dioxin-like PCBs are
shown in Table 9. In the unadjusted models, dioxin-like and non-
dioxin-like PCBs were significantly associated with breast cancer,
ovarian cancer and uterine cancer. In the age and race/ethnicity
adjusted models, dioxin-like PCBs were significantly associated with
ovarian cancer (OR of 1.95, 95% CI: 1.25-3.05). Non-dioxin-like PCBs
were significantly associated cervical cancer (OR of 1.29, 95% CI:
1.18-1.40), ovarian cancer (OR of 1.32, 95% CI: 1.02-1.69), and uterine
cancer (OR of 1.11, 95% CI: 1.01-1.22). After adjusting for age, race/
ethnicity, BMI, and age at menarche dioxin-like PCBs remained
significantly associated with ovarian cancer risk (OR of 2.02, 95% CI:
1.06-3.85) and non-dioxin-like PCBs remained significantly associated
with uterine cancer risk (OR of 1.12, 95% CI: 1.03-1.23) (Table 9). We
further analyzed gynecologic cancer risk of dioxin-like and non-
dioxin-like PCBs using the following two groups: <LOD to 50th
percentile (reference group) and ≥ 50th percentile. In subjects with
PCB levels ≥ 50th percentile, breast cancer, ovarian cancer, and uterine
cancer were associated with dioxin-like and non-dioxin-like PCBs in
the unadjusted models. Non-dioxin-like PCBs were significantly
associated with cervical cancer risk and ovarian cancer risk in the age
and race/ethnicity adjusted models [ORs of 2.59, 95% CI: 1.04-6.42
and 6.62, 95% CI: 1.50-29.2], respectively. Dioxin-like PCBs were
associated with the risk of ovarian cancer in the age and race/ethnicity
adjusted models [OR of 6.32 (95% CI: 1.44-27.7). In the final adjusted
models (age, race/ethnicity, BMI, age at menarche) the risk of ovarian
cancer remained significant in dioxin-like PCBs [OR of 5.71 (95% CI:
1.12-29.2)] and non-dioxin-like PCBs [OR of 5.99 (95% CI: 1.20-29.9)
and the risk of uterine cancer remained significant in non-dioxin-
PCBs [OR of 4.85 (95% CI: 1.32-17.8) (Table 9).
Cases/Noncases Unadjusted OR (95% CI) Adjusted OR1 (95% CI) Adjusted OR2a,b (95% CI)
Breast Cancer
Dioxin-like PCBs3 43/1953 1.50 (1.27-1.78)a 1.50 (1.27-1.77)a 1.08 (0.80-1.45)
Dioxin-like PCBs_503,5
<LOD to 50% 4/985 1.00 1.00 1.00
≥ 50% 39/968 5.23 (2.25-12.2)a 1.55 (0.49-4.90) 1.90 (0.33-10.8)
Non- Dioxin-like PCBs4 43/1941 1.28 (1.18-1.38)a 1.14 (1.00-1.29)b 1.12 (0.98-1.28)
Non-Dioxin-like PCBs_504,5
<LOD to 50% 2/997 1.00 1.00 1.00
≥ 50% 41/944 12.7 (2.58-62.2)b 5.40 (0.87-33.5) 4.27 (0.68-26.8)
Cervical Cancer
Dioxin-like PCBs3 27/1954 1.15(0.91-1.45) 1.13 (0.82-1.56) 1.10 (0.78-1.55)
Dioxin-like PCBs_503,5
<LOD to 50% 12/985 1.00 1.00 1.00
≥ 50% 15/968 1.13 (0.50-2.58) 1.04 (0.90-1.20) 0.80 (0.27-2.38)
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Non- Dioxin-like PCBs4 26/1941 1.05 (0.94-1.16) 1.29 (1.18-1.40)a 1.02 (0.87-1.19)
Non-Dioxin-like PCBs_504,5 9/997 1.00 1.00 1.00
<LOD to 50% 17/944 2.38 (1.14-4.94)b 2.59 (1.04-6.42)b 2.51 (0.94-6.68)
≥ 50% 
Ovarian Cancer
Dioxin-like PCBs3 11/1954 1.61 (1.19-2.17)a 1.95 (1.25-3.05)b 2.02 (1.06-3.85)b
Dioxin-like PCBs_503,5
<LOD to 50% 2/985 1.00 1.00 1.00
≥ 50% 9/968 5.26 (1.51-18.4)b 6.32 (1.44-27.7)b 5.71 (1.12-29.2)b
Non- Dioxin-like PCBs4 11/1941 1.24 (1.01-1.53)b 1.32 (1.02-1.69)b 1.30 (0.98-1.72)
Non-Dioxin-like PCBs_504,5
<LOD to 50% 2/997 1.00 1.00 1.00
≥ 50% 9/994 5.51 (1.56-19.5)b 6.62 (1.50-29.2)b 5.99 (1.20-29.9)b
Uterine Cancer
Dioxin-like PCBs3 26/1954 1.16 (0.88-1.52) 1.02 (0.76-1.37) 1.10 (0.83-1.46)
Dioxin-like PCBs_503,5
<LOD to 50% 10/985 1.00 1.00 1.00
≥ 50% 16/968 1.14 (1.04-1.25)b 0.87 (0.18-4.21) 1.24 (0.29-5.28)
Non- Dioxin-like PCBs4 25/1941 1.28 (1.18-1.38)b 1.11 (1.01-1.22)b 1.12 (1.03-1.23)b
Non-Dioxin-like PCBs_504
<LOD to 50% 7/997 1.00 1.00 1.00
≥ 50% 18/944 4.14 (1.44-11.3)b 3.53 (0.96-13.1) 4.85 (1.32-17.8)b
Table 9: Estimated ORs (95% CIs) of having a gynecological cancer by concentrations of Dioxin-like and non-Dioxin-like PCBs among women ≥
20 years of age, NHANES 1999-2004. 1Adjusted for age and race/ethnicity. 2Adjusted for age, race/ethnicity, BMI, age at menarche. aCases/
Noncases in dioxin-like PCBs : 40/1749 for breast cancer, 24/1749 for cervical cancer, 10/1749 for ovarian cancer, 25/1749 for uterine cancer.
bCases/Noncases in non-dioxin-like PCBs: 40/1737 for breast cancer, 23/1737 for cervical cancer, 10/1737 for ovarian cancer, 24/1737 for uterine
cancer. 3Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (074 + 118). 4Non-Dioxin-like PCBs: Sum of lipid adjusted
and log transformed PCB Congeners (099 + 138 + 153 + 180). 5Serum PCB Levels < 50th percentile vs ≥ 50th percentile. Significance ap<0.0001,
bp<0.05.
Estimated ORs and 95% CIs for the risk of having cervical, ovarian,
or uterine cancer and the eight phthalate metabolites, the sum of
DEHP, and total phthalates are shown in Tables 10-12. We analyzed the
phthalate levels in the following groups: <LOD to 50th percentile
(reference group) and ≥ 50th percentile. Results are presented for two
logistic regression models: age and race adjusted; and age, race/
ethnicity, BMI, and age at menarche adjusted. Results were not
presented for unadjusted models age because the derived ORs and 95%
CIs did not differ from the models presented. A significant association
between cervical cancer and phthalates was not found in any of the
models (Table 10).
Metabolite1 No.Cases
Non
cases
Adjusted OR2 (95%
CI)
Adjusted OR3 (95%
CI)
MBP
<LOD to
50% 10 1045 1.00 1.00
≥ 50% 18 1678 0.70 (0.25-1.97) 0.64 (0.22-1.85)
MEP
<LOD to
50% 14 1106 1.00 1.00
≥ 50% 14 1616 0.91 (0.39-2.14) 0.80 (0.33-1.97)
MEHP
<LOD to
50% 12 1339 1.00 1.00
≥ 50% 16 1376 0.95 (0.46-1.96) 0.91 (0.44-1.88)
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MBzP
<LOD to
50% 10 1205 1.00 1.00
≥ 50% 18 1517 1.07(0.51-2.22) 1.04 (0.49-2.21)
MCCP
<LOD to
50% 16 1396 1.00 1.00
≥ 50% 12 1326 0.73 (0.38-1.38) 0.77 (0.41-1.47)
MEHHP
<LOD to
50% 10 1280 1.00 100
≥ 50% 18 1443 1.10 (0.39-3.11) 1.00 (0.36-2.77)
MEOHP
<LOD to
50% 11 1267 1.00 1.00
≥ 50% 17 1456 0.77 (0.31-1.87) 0.68 (0.28-1.65)
MIB
<LOD to
50% 14 1260 1.00 1.00
≥ 50% 14 1457 0.81 (0.35-1.87) 0.85 (0.35-2.03)
DEHP
<LOD to
50% 12 1301 1.00 1.00
≥ 50% 16 1422 0.79 (0.33-1.92) 0.73 (0.30-1.76)
Total
<LOD to
50% 12 1423 1.00 1.00
≥ 50% 16 1300 0.98 (0.44-2.17) 0.81 (0.38-1.74)
Table 10: Estimated ORs (95% CIs) of cervical cancer by concentration
of creatinine corrected urinary phthalate metabolite, among women ≥
20 years of age NHANES 2003-2010. 1 Log transformed and creatinine
adjusted urinary phthalates (ng/mg). 2Adjusted for age and race/
ethnicity. 3Adjusted for age, race/ethnicity, BMI, age at menarche;
Cases/Noncases: 26/2410 in MBP, MEHHP, MEOHP, MIB, DEHP;
26/2409 in MEP, MBzP, MCCP; 26/2403 in MEHP. Significance
ap<0.0001, bp<0.05.
Estimated ORs and 95% CIs for the risk of ovarian cancer and
uterine cancer by concentration of the eight phthalate metabolites, the
sum of DEHP, and total phthalates are shown in Tables 11 and 12. In
the age and race adjusted model, MEHHP showed a weak association
with ovarian cancer [OR of 3.63 (95% CI: 1.00-13.2) p=.0497],
however this association remained significant after adjusting for age,
race/ethnicity, BMI, and age at menarche (Table 11). None of the
phthalates were significantly associated with the risk of uterine cancer
(Table 12).
Metabolite1 No.Cases
Noncas
es
Adjusted OR2 (95%
CI)
Adjusted OR3 (95%
CI)
MBP
<LOD to
50% 6 1045 1.00 1.00
≥ 50% 14 1678 1.96 (0.61-6.31) 1.48 (0.42-5.19)
MEP
<LOD to
50% 11 1106 1.00 1.00
≥ 50% 9 1616 0.43 (0.17-1.12) 0.38 (0.11-1.30)
MEHP
<LOD to
50% 7 1339 1.00 1.00
≥ 50% 13 1376 2.56 (0.92-7.10) 1.91 (0.61-5.94)
MBzP
<LOD to
50% 10 1205 1.00 1.00
≥ 50% 10 1517 1.65 (0.56-4.83) 1.59 (0.50-5.11)
MCCP
<LOD to
50% 12 1396 1.00 1.00
≥ 50% 8 1326 1.13 (0.35-3.60) 1.24 (0.36-4.25)
MEHHP
<LOD to
50% 4 1280 1.00 1.00
≥ 50% 16 1443 3.63 (1.00-13.2)b 2.73 (0.67-11.1)
MEOHP
<LOD to
50% 4 1267 1.00 1.00
≥ 50% 16 1456 3.58(0.98-13.1) 2.67 (0.678-10.6)
MIB
<LOD to
50% 11 1260 1.00 1.00
≥ 50% 9 1457 0.57 (0.16-1.99) 0.61 (0.13-2.83)
DEHP
<LOD to
50% 6 1301 1.00 1.00
≥ 50% 14 1422 2.88 (0.95-8.76) 2.29 (0.64-8.23)
Total
<LOD to
50% 9 1423 1.00 1.00
≥ 50% 11 1300 1.21 (0.46-3.17) 1.38 (0.46-4.17)
Table 11: Estimated ORs (95% CIs) of ovarian cancer by concentration
of creatinine corrected urinary phthalate metabolite among women ≥
20 years of age, NHANES 2003-2010. 1Log transformed and creatinine
adjusted urinary phthalates (ng/mg). 2Adjusted for age and race/
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ethnicity. 3Adjusted for age, race/ethnicity, BMI, age at menarche;
Cases/Noncases: 17/2410 in MBP, MEHHP, MEOHP, MIB, DEHP;
17/2409 in MEP, MBzP, MCCP; 17/2403 in MEHP. Significance
ap<0.0001, bp<0.05.
Metabolite1 No.Cases
Non
cases
Adjusted OR2 (95%
CI)
Adjusted OR3
(95% CI)
MBP
<LOD to
50% 10 1045 1.00 1.00
≥ 50% 17 1678 1.17 (0.36-3.78) 1.11 (0.33-3.68)
MEP
<LOD to
50% 12 1106 1.00 1.00
≥ 50% 15 1616 1.02 (0.47-2.20) 0.99 (0.46-2.12)
MEHP
<LOD to
50% 21 1339 1.00 1.00
≥ 50% 6 1376 0.34 (0.11-1.03) 0.34 (0.11-1.09)
MBzP
<LOD to
50% 16 1205 1.00 1.00
≥ 50% 11 1517 0.59 (0.23-1.48) 0.55 (0.21-1.43)
MCCP
<LOD to
50% 14 1396 1.00 1.00
≥ 50% 13 1326 0.88 (0.32-2.45) 0.85 (0.31-2.32)
MEHHP 
<LOD to
50% 10 1280 1.00 1.00
≥ 50% 17 1443 1.55 (0.65-3.70) 1.43 (0.61-3.34)
MEOHP
<LOD to
50% 11 1267 1.00 1.00
≥ 50% 16 1450 1.02 (0.46-2.23) 0.95 (0.45-2.02)
MIB
<LOD to
50% 12 1260 1.00 1.00
≥ 50% 15 2337 1.20 (0.45-3.17) 1.21 (0.45-3.20)
DEHP
<LOD to
50% 15 1301 1.00 1.00
≥ 50% 12 1422 0.92 (0.40-2.12) 0.87 (0.39-1.93)
Total
<LOD to
50% 13 1423 1.00 1.00
≥ 50% 14 1300 0.98(0.34-2.84) 0.92 (0.30-2.79)
Table 12: Estimated ORs (95% CIs) of uterine cancer by concentration
of creatinine corrected urinary phthalate metabolite among women ≥
20 years of age, NHANES 2003-2010. 1Log transformed and creatinine
adjusted urinary phthalates (ng/mg).2Adjusted for age and race/
ethnicity 3Adjusted for age, race/ethnicity, BMI, age at menarche;
Cases/Noncases: 27/2410 in MBP, MEHHP, MEOHP, MIB, DEHP;
27/2409 in MEP, MBzP, MCCP; 27/2403 in MEHP Significance
ap<0.0001, bp<0.05.
Estimated ORs and 95% confidence intervals for the risk of having
cervical, ovarian, or uterine cancers by concentration of BPA are
shown in Table 13. The following two groups were used to estimate
gynecologic cancer risk: <LOD to 50th percentile (reference group)
and ≥ 50th percentile. Results are presented for three logistic
regression models: unadjusted; age and race/ethnicity adjusted; and
age, race/ethnicity, BMI, and age at menarche adjusted. None of the
models showed a significant association between BPA and cervical
cancer, ovarian cancer, or uterine cancer (Table 13).
 
No.
Case
s
No.
Noncas
es
Unadjusted OR
(95% CI)
Adjusted
OR1 (95%
CI)
Adjusted
OR2 (95% CI)
Cervical Cancer
<LOD to
50% 6 985 1.00 1.00 1.00
≥ 50% 9 1082 1.34 (0.37-4.81) 1.39(0.39-4.91)
1.33
(0.42-4.18)
Ovarian Cancer
<LOD to
50% 6 985 1.00 1.00 1.00
≥ 50% 10 1082 1.57 (0.43-5.76) 1.64(0.43-6.25)
1.41
(0.30-6.70)
Uterine Cancer
<LOD to
50% 13 985 1.00 1.00 1.00
≥ 50% 9 1082 0.58 (0.27-1.28) 0.65(0.30-1.41)
0.57
(0.25-1.29)
Table 13: Estimated ORs (95% CIs) of a gynecological cancer by
concentration of creatinine adjusted urinary BPA among women ≥ 20
years of age, NHANES 2005-2010. Log –transformed and creatinine
adjusted BPA measurements (ng/mg); NHANES 2005-2010. 1Adjusted
for age and race/ethnicity. 2Adjusted for age, race/ethnicity, BMI, age at
menarche; Noncases=1821. Significance ap<0.0001, bp<0.05.
Discussion
In this cross-sectional study of women 20-85 years of age, we
separately evaluated 6 individual PCB congeners, the sum of dioxin-
like PCBs, the sum of non-dioxin-like PCBs, eight phthalate
metabolites, the sum of DEHP, the sum of total phthalates, and BPA in
association with gynecological cancers (cervical, ovarian, and uterine)
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in women. One of the major findings emerged from this study pointed
out a possible association between chronic exposure to xenooestrogen
- polychlorinated biphenyls and increased risk of developing ovarian
and uterine cancers. Higher PCB levels were detected in the women
diagnosed with ovarian cancer and cervical cancer compared to
women never diagnosed with cancer. PCBs showed the most
significant associations with all three cancers. After adjusting for all
confounding variables, women with ovarian cancer had significant
associations with PCB 74 and 118, and therefore the dioxin-like PCBs.
Dioxin-like PCBs were significantly associated with ovarian cancer and
non-dioxin-like PCBs were significantly associated with ovarian and
uterine cancers, after adjusting for age, race, BMI, and age at
menarche. In our study, exposure to PCB 138 showed the strongest
associations to significantly increase the risk of cervical and uterine
cancers. Epidemiological studies on the association of PCBs with
cervical, ovarian, and uterine cancers are lacking, but results of this
study are consistent with our findings in breast cancer studies that also
reported higher PCB levels in breast cancer cases compared to controls
[8]. Our findings are also in agreement with another study that showed
increased levels of PCB 28; PCB 52; PCB 101; PCB 138; PCB 153 and
PCB 180 in abdominal adipose tissue in cases of endometrial stromal
sarcomas - rare uterine tumors [31]. While these results do not provide
any evidence of causal associations, it is noteworthy that NHANES
samples show higher body burdens of estrogenic PCB congeners in
women with ovarian and uterine cancer compared to women never
diagnosed with cancer. We and others have shown that many genes
that respond to estrogen play important role to control the
development and progression of cervical, ovarian and uterine cancers
[3,4]. We have recently reported that all three EDDs–PCBs, phthalates,
and BPA influence five common genes—CYP19A1, EGFR, ESR2, FOS,
and IGF1 in breast cancer as well as in endometriosis [4]. These genes
are environmentally and estrogen responsive and altered in human
breast and uterine tumors, endometriosis lesions, and participate in
carcinogenesis pathways. These findings suggest that PCB-induced
dysregulation of estrogen signaling pathway may contribute to the
increased risk of gynecological cancers (cervical, ovarian, and uterine)
in women.
Epidemiological studies on the association with phthalates and BPA
with cervical, ovarian, and uterine cancers are lacking or limited. In
this study MEHP levels was found to be higher in women never
diagnosed with cancer. Mono-(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP) was weakly associated (p=0.0497) with ovarian cancer risk
in the model adjusted for age and race but did not remain significantly
associated when the additional variables of BMI and age at menarche
were added. Higher levels of BPA were found in the urine samples of
women with cervical cancer only.
There are a number of limitations in our study. The most important
is its cross-sectional design with self-reported data that may over
report and does not allow causal inferences. Self-reported data
increases the risk of misclassification bias of cases and controls with
the possibility of undiagnosed or incorrectly reported cancer cases. In
the PCB data analysis, we had relatively small sample sizes for cervical
cancer (n=27), ovarian cancer (n=11), and uterine cancer (n=26),
resulting in decreased statistical power within subgroup analyses.
Missing data on confounding reproductive variables such as parity and
lactation is another limitation to this study. Furthermore, observed
associations can be potentially confounded by the lack of information
on family history of hormonal cancers. Nonetheless, this cross-
sectional study design has strengths that include a large sample survey
size, availability of biological measurements of environmental
contaminants, and oversampling of minority populations. We conclude
that higher serum PCB concentrations in cervical, ovarian and uterine
cancers subjects may be as a result of past exposures to higher
environmental PCB concentrations and chronic exposure to
xenooestrogen - PCBs may increase the risk of developing cervical,
ovarian and uterine cancers. In addition, this study also presents a
design to analyze individual as well as the additive, synergistic, or
antagonistic combined effects of EEDs within a class or across classes.
Our findings, coupled with the lack of available epidemiological
evidence concerning EEDs exposures and cervical, ovarian, and
uterine cancers warrants the need for future prospective studies to
determine the potential role of environmental exposures to PCBs,
phthalates, and BPA in the development of gynecologic cancers.
Additional research is also needed to consider cumulative exposures of
EEDs and their effects on the development of gynecological cancers.
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